Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: CALGB 80802 Principal Investigator: Tan, Benjamin
Title: Phase III randomized study of Sorafenib plus Doxorubicin versus Sorafenib in patients with Advanced Hepatocellular Carcinoma (HCC)
Phase: III Disease Site: Liver
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to compare the effects (good and bad) of the drug sorafenib with the combination of sorafenib plus doxorubicin on patients and their advanced primary liver cancer to find out which is better.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)